1 “...Portable US is primarily used for diagnostic purposes, but therapeutic uses (e.g., US guided...”

2 “... pregnancy to the next and confounding test results. The cost of NIPT ranges from US$800 to US$2000...”

3 “..., and mortality, with an additional cost of US$30,000 per survivor in the US. Different antiseptic solutions...”

4 “.... There are two commercially available systems for TAVR: Edwards Sapien (LifeSciences, Irvine, CA, US...”

5 “.... There are two commercially available systems for TAVR: Edwards Sapien (LifeSciences, Irvine, CA, US...”

6 “... nitinol stent. It received European regulatory approval in January 2013, and is currently undergoing US...”

7 “... nitinol stent. It received European regulatory approval in January 2013, and is currently undergoing US...”

8 “... 000 in those over 75 years of age in the US as of 2005. The reduced ability to clear secretions from...”

9 “... 000 in those over 75 years of age in the US as of 2005. The reduced ability to clear secretions from...”

10 “...The Food and Drug Administration in the U.S. approved naltrexone (XR-NTX) in 2010, however...”

11 “...The Food and Drug Administration in the U.S. approved naltrexone (XR-NTX) in 2010, however...”

12 “... limb amputations due to diabetes in the US originating with foot ulcerations. Successful treatment...”

13 “... of B-cell non-Hodgkin lymphoma (NHL). It is approved for use by regulators in European Union and the US...”

14 “.... PAH is associated with poor overall prognosis. A US national registry study (conducted prior...”

15 “.... PAH is associated with poor overall prognosis. A US national registry study (conducted prior...”

16 “..., this medication list could potentially include newer buprenorphine formulations available in the US. The purpose...”

17 “... of B-cell non-Hodgkin lymphoma (NHL). It is approved for use by regulators in European Union and the US...”

18 “..., this medication list could potentially include newer buprenorphine formulations available in the US. The purpose...”

19 “... on average in the U.S., largely as a result of complications and surveillance of recurrence. In the last two...”

20 “... on average in the U.S., largely as a result of complications and surveillance of recurrence. In the last two...”